AbCellera Biologics Inc. Common Shares (ABCL) Stock Price

ABCLStock

$12.50+141.69%52W

Market Cap$4.05B

P/E—

PEG Ratio—

Div yield—

Beta1.39

ABCL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)227.73%

Price vs S&P 500 (4W)97.52%

VGM Score48.92

Book Value / Share (Quarterly)$2.92

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.31%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)198.28%

Net Profit Margin (TTM)-248.83%

EPS (TTM)$-0.54

10-Day Avg Trading Volume10.99M

EPS Excl Extra (TTM)$-0.54

Revenue Growth (5Y)-20.27%

EPS (Annual)$-0.49

ROI (Annual)-15.14%

Net Profit Margin (5Y Avg)-214.23%

Cash / Share (Quarterly)$1.76

Revenue Growth QoQ (YoY)-76.29%

ROA (Last FY)-10.79%

Revenue Growth TTM (YoY)101.28%

EBITD / Share (TTM)$-0.66

ROE (5Y Avg)-3.09%

Operating Margin (TTM)-340.25%

Cash Flow / Share (Annual)$-0.58

P/B Ratio3.75x

P/B Ratio (Quarterly)2.68x

Net Income / Employee (Annual)$-260,500

EV / Revenue (TTM)49.01x

Net Interest Coverage (TTM)79.25x

ROA (TTM)-12.36%

EV / EBITDA (TTM)13.27x

EPS Incl Extra (Annual)$-0.49

Current Ratio (Annual)11.32x

Quick Ratio (Quarterly)12.42x

3-Month Avg Trading Volume8.27M

52-Week Price Return141.69%

EV / Free Cash Flow (Annual)3.61x

Revenue / Employee (TTM)$117,700

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)44.77x

Asset Turnover (Annual)0.06x

52-Week High$12.15

Operating Margin (5Y Avg)-381.08%

EPS Excl Extra (Annual)$-0.49

CapEx CAGR (5Y)23.81%

Tangible BV CAGR (5Y)5.36%

26-Week Price Return238.98%

Quick Ratio (Annual)11.08x

13-Week Price Return106.42%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.77x

Enterprise Value$3.24B

Revenue / Share Growth (5Y)-21.90%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)0.86%

Revenue / Employee (Annual)$133,700

Pretax Margin (Annual)-236.39%

Cash / Share (Annual)$1.78

3-Month Return Std Dev110.65%

Net Income / Employee (TTM)$-293,000

ROE (Last FY)-15.14%

Net Interest Coverage (Annual)-1402.93x

EPS Basic Excl Extra (Annual)$-0.49

P/FCF (TTM)141.38x

Receivables Turnover (TTM)2.01x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.54

Receivables Turnover (Annual)1.63x

ROI (TTM)-17.49%

P/S Ratio (TTM)50.83x

Pretax Margin (5Y Avg)-256.28%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$3.09

Price vs S&P 500 (52W)123.38%

Year-to-Date Return210.23%

5-Day Price Return-4.59%

EPS Normalized (Annual)$-0.49

ROA (5Y Avg)-2.13%

Net Profit Margin (Annual)-194.88%

Month-to-Date Return85.81%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.65

Operating Margin (Annual)-288.98%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-3.09%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.54

P/TBV (Quarterly)2.79x

P/B Ratio (Annual)1.06x

Pretax Margin (TTM)-297.36%

Book Value / Share (Annual)$3.22

Price vs S&P 500 (13W)103.63%

Beta1.39x

P/FCF (Annual)16.43x

Revenue / Share (TTM)$0.22

ROE (TTM)-17.49%

52-Week Low$2.75

vGradeD

gGradeD

mGradeA

vgmGradeC

ABCL Earnings Surprise History

Q2 25-0.12est. -0.16

Q3 25-0.19est. -0.16

Q4 25-0.03est. -0.18

Q1 26-0.14est. -0.20

Q2 26-0.18est. -0.17

ABCL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ABCLAbCellera Biologics Inc. Common Shares	D	D	A	$12.50
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About AbCellera Biologics Inc. Common Shares

AbCellera is an antibody discovery platform that accelerates clinical candidate identification through proprietary hardware, software, and data science. The company partners with biotechnology and pharmaceutical firms to discover optimized antibody therapies faster and more efficiently than conventional discovery methods. AbCellera's integrated platform reduces time to clinic and de-risks development programs for its partners.